In a Parkinson’s disease patient taking rasagiline and not yet on sertraline, what non‑serotonergic antidepressant should be started and how should it be dosed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Non-Serotonergic Antidepressant for Parkinson's Disease Patient on Rasagiline

In a Parkinson's disease patient taking rasagiline who needs antidepressant therapy, start bupropion at 37.5 mg every morning, increasing by 37.5 mg every 3 days to a target of 150 mg twice daily (second dose before 3 PM). 1

Rationale for Bupropion Selection

Bupropion is the optimal choice in this clinical scenario for several critical reasons:

  • No serotonergic activity: Unlike SSRIs, SNRIs, and tricyclic antidepressants, bupropion works primarily through dopamine and norepinephrine reuptake inhibition without affecting serotonin pathways 1
  • Avoids serotonin syndrome risk: The FDA label for rasagiline explicitly contraindicates use with serotonergic agents due to risk of serotonin syndrome 2. While rasagiline is a selective MAO-B inhibitor (not MAO-A), the combination with serotonergic antidepressants still carries theoretical risk that manufacturers warn against
  • Activating properties: Bupropion tends to be activating and can rapidly improve energy levels, which is particularly beneficial for the apathy and fatigue commonly seen in Parkinson's disease depression 1
  • Sexual function preservation: Bupropion has lower rates of sexual dysfunction compared to SSRIs, an important quality-of-life consideration 3

Specific Dosing Protocol

Starting dose: 37.5 mg every morning
Titration: Increase by 37.5 mg every 3 days as tolerated
Target dose: 150 mg twice daily
Maximum dose: 150 mg twice daily (300 mg total daily)
Timing: Give second dose before 3 PM to minimize insomnia risk 1

Critical Contraindications and Precautions

Absolute contraindication: Do not use bupropion in patients with:

  • Seizure disorders or history of seizures
  • Current agitation or severe anxiety (bupropion's activating properties may worsen these symptoms) 1

Alternative Non-Serotonergic Options

If bupropion is contraindicated or not tolerated, consider:

Nortriptyline (Secondary-Amine TCA)

  • Starting dose: 10 mg at bedtime
  • Titration: Increase by 10-25 mg every 3-7 days
  • Maximum dose: 40 mg per day (given in divided doses)
  • Advantages: More sedating than bupropion (useful for agitated depression with insomnia); therapeutic blood level window of 50-150 ng/mL 1
  • Cautions: Anticholinergic effects (dry mouth, constipation, urinary retention, orthostatic hypotension) can worsen PD symptoms; may cause tachycardia 4, 1

Desipramine (Secondary-Amine TCA)

  • Starting dose: 10-25 mg in the morning
  • Maximum dose: 150 mg in the morning
  • Advantages: Tends to be activating and reduces apathy; lower risk for cardiotoxic, hypotensive, and anticholinergic effects compared to tertiary amine TCAs 1
  • Cautions: May cause tachycardia; blood levels may be helpful for monitoring 1

Important Clinical Considerations

Avoid all serotonergic agents while on rasagiline, including:

  • SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine)
  • SNRIs (venlafaxine, duloxetine)
  • Tertiary amine TCAs (amitriptyline, imipramine)
  • Tramadol, meperidine, methadone, propoxyphene
  • Dextromethorphan
  • St. John's wort 2

Monitoring requirements:

  • Assess patient status within 1-2 weeks of initiation 3
  • Monitor for suicidal ideation, especially in first 1-2 months 3
  • If inadequate response after 6-8 weeks at therapeutic dose, modify treatment 3

Emerging Evidence on Rasagiline-Antidepressant Combinations

While the FDA label contraindicates serotonergic antidepressants with rasagiline 2, recent research suggests this combination may be safer than previously thought. A large retrospective study of 1,504 PD patients found zero cases of serotonin syndrome in 471 patients taking rasagiline plus antidepressants (mostly SSRIs) 5. The ADAGIO study post-hoc analysis showed that 191 patients taking rasagiline with antidepressants had improved depression and cognition scores with no serious adverse events suggestive of serotonin syndrome 6.

However, given the FDA contraindication and medicolegal implications, bupropion remains the safest first-line choice until formal guidelines are updated. If a serotonergic antidepressant is absolutely necessary due to treatment failure with non-serotonergic options, this should be done with extreme caution, informed consent, close monitoring, and ideally specialist consultation.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.